Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Company Research
Source: Yahoo! Finance
Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “In 2024, we made significant advancements in our oral small molecule obesity portfolio delivering positive data for aleniglipron and selecting our first-in-class oral small molecule amylin receptor agonist. We completed a $547 million financing putting us in a strong financial position,” said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics.
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswire
- Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=GPCR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.MarketBeat
GPCR
Sec Filings
- 12/10/25 - Form 8-K
- 12/10/25 - Form 424B5
- 12/10/25 - Form 4
- GPCR's page on the SEC website